Iterum Initiates SURE 2 and SURE 3 Phase 3 Clinical Trials of IV and Oral Sulopenem in Complicated Urinary Tract and Complicated Intra-abdominal Infections Remaining two of three planned Phase 3 pivotal trials now underway for Iterum’s lead antibiotic product...
Iterum Initiates SURE 1, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections First of three planned Phase 3 pivotal trials now underway for Iterum’s oral antibiotic Oral sulopenem, if approved, could be the first antibiotic for...
Aptinyx Initiates Phase 1 Study of NYX-458 Development in Parkinson’s Disease Cognitive Impairment Planned EVANSTON, Ill., Aug. 02, 2018 (GLOBE NEWSWIRE) — Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies...
Rallybio Further Expands Drug Acquisition and Development Capabilities Rallybio Welcomes Laura Ekas, PhD and Eric Watsky, MD, Further Expanding Rallybio’s Drug Acquisition and Development Capabilities FARMINGTON, Connecticut, August 7, 2018 – Rallybio LLC, a...
Harpoon Therapeutics treats first patient with HPN424 in phase I clinical trial of metastatic castration-resistant prostate cancer (mCRPC) patients. HPN424, First-in-Class TriTAC™ T Cell Redirection Therapy, Targets Prostate-Specific Membrane Antigen (PSMA) Clinical...
Recent Comments